Skip to content
My WebMD Sign In, Sign Up

Breast Cancer Health Center

Font Size
A
A
A

Breast Cancer Chemo Drug for Whom?

Drug, Called Taxol, May Only Benefit Certain Women With Breast Cancer
By
WebMD Health News
Reviewed by Louise Chang, MD

Taxol HER2 Breast Cancer

Oct. 10, 2007 -- The breast cancer chemotherapy drug Taxol may not help most breast cancer patients, researchers report in The New England Journal of Medicine.

The key finding: Adding Taxol to a chemotherapy regimen may only benefit women who have HER2-positive breast cancer, in which breast cancer has a high level of a protein called HER2.

That's about 15% to 20% of all breast cancer patients, according to the researchers, who included the University of Michigan's Daniel Hayes, MD.

Hayes' team isn't recommending that any breast cancer patients abandon Taxol.

"We think the stakes are too high" to change treatment recommendations until further research is done, Hayes says in a news release.

But cancer doctors "have a responsibility to patients to be aware" of the study, states a journal editorial.

"The days of 'one size fits all' therapy for patients with breast cancer are coming to an end," writes editorialist Anne Moore, MD, of New York's Weill Cornell Medical College.

Taxol for Breast Cancer

Hayes and colleagues reviewed data from a breast cancer study conducted in the 1990s.

Though the data weren't new, the analysis was, and it was "appropriate" to look back at that data, according to editorialist Moore.

The study included 3,121 women whose breast cancer had spread to their lymph nodes and who had already had breast cancer surgery.

All of the women got two chemotherapy drugs -- Adriamycin and Cytoxan. Afterward, about half of the women got further chemotherapy treatment with Taxol.

Taxol and HER2

Over the next five years, women with HER2-positive breast cancer who got Taxol were more likely to survive without breast cancer recurrence, compared with those with HER2-positive breast cancer who didn't get Taxol.

But those Taxol benefits only included women with HER2-positive breast cancer, the study shows. In women with HER2-negative breast cancer, Taxol didn't appear to affect survival or recurrence.

The findings weren't affected by whether the women's breast tumors were sensitive to the hormone estrogen.

In the journal, several of Hayes' colleagues report financial ties to Bristol-Myers Squibb, the drug company that makes Taxol.

Today on WebMD

Breast Cancer Health Check
HEALTH CHECK
breast cancer overview slideshow
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
senior woman
Article
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW